2017 Annual Meeting
(136b) A New Approach in Applying CSP for the Pharmaceutical Industry
The ability to solve solid-state structures through organic crystal structure prediction (CSP) has remained elusive despite many years of industry and academic research. More recently, however, advances in computer technology and modeling have combined to rekindle enthusiasm for CSP. The pharmaceutical industry is particularly interested in CSP due to the importance of solid-state structures and properties in the drug development process. Real-time applications of several CSP technologies are currently at the proof-of-concept stage.
XtalPi, the industry pioneer in innovative CSP technology, deploys an advanced algorithm platform as part of its intelligent digital solid-state prediction technology. The XtalPi CSP technology has emerged from proof-of-concept through rigorous and extensive internal and external challenges, and is particularly well suited for the pharmaceutical industry. Indeed, XtalPi has already integrated its CSP technology into drug design and pharmaceutical product development in collaboration with industry partners.